+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

KOL Perspectives: BTK Inhibitors in RA

  • ID: 4701805
  • Drug Pipelines
  • August 2018
  • Region: Global
  • 26 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AbbVie
  • BMS
  • Lilly
  • Merck
  • Roche
  • MORE
Summary

This KOL Insight briefing focuses on KOLs views of BTK Inhibitors in RA.

Questions topics -
  • Awareness and potential of BTK inhibitors in RA
  • Perceptions of BMS-986142’s Phase IItrial design
  • Impact of poseltinib discontinuation on existing perception of BTK inhibitors in RA
Key Highlights
  • Of the named BTK inhibitors, KOLs demonstrated the greatest awareness of BMS-986142, despite its lack of Phase II data
  • KOLs were divided over BMS-986142’s ability to achieve ACR70 by Week 12 in a refractory patient population
  • For the majority of KOLs, poseltinib’s discontinuation had little to no impact on their existing perception of BTK inhibitors in RA.
Scope
  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
  • 5 Europe-based & 5 N. America-based
  • Interviews performed during Q2 2018
KOL data is analyzed to produce -
  • Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts
Reasons to Buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on BTK Inhibitors in RA
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of RA
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • BMS
  • Lilly
  • Merck
  • Roche
  • MORE
  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications
  • Appendix
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • BMS
  • Lilly
  • Roche
  • Merck
  • AbbVie
Note: Product cover images may vary from those shown
Adroll
adroll